Article
Extensive changes in liver gene expression induced by hereditary tyrosinemia type I are not normalized by treatment with 2-(2-nitro-4-trifluoromethylbenzoyl)-1,3-cyclohexanedione (NTBC).
Journal of hepatology - 1 Dec 2003
Luijerink Marjanka C, Jacobs Saskia M M, van Beurden Ellen A C M, Koornneef Leander P, Klomp Leo W J, Berger Ruud, van den Berg Inge E T
Abstract excerpt
BACKGROUND: Hereditary Tyrosinemia type I, caused by deficiency of fumarylacetoacetate hydrolase (FAH), is characterized by liver and kidney damage. Administration of 2-(2-nitro-4-trifluoromethylbenzoyl)-1,3-cyclohexanedione (NTBC) corrects the tyrosinemia phenotype, but does not prevent development of hepatocellular carcinoma. AIM: To gain insight into the pathophysiological changes associated with liver damage...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.